Phase II Trial of Nab-paclitaxel (Abraxane) in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

Phase II Trial of Nab-paclitaxel (Abraxane) in Patients With Relapsed or Refractory Multiple Myeloma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Oct 2017 Status changed from active, no longer recruiting to discontinued.
    • 20 Dec 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
    • 03 Jun 2016 Planned primary completion date changed from 1 Feb 2015 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top